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Abstract
The metabolism of the amyloid precursor protein (APP) and tau are central to the pathobiology of Alzheimer’s disease (AD).
We have examined the in vivo turnover of APP, secreted APP (sAPP), Ab and tau in the wild-type and Tg2576 mouse brain
using cycloheximide to block protein synthesis. In spite of overexpression of APP in the Tg2576 mouse, APP is rapidly
degraded, similar to the rapid turnover of the endogenous protein in the wild-type mouse. sAPP is cleared from the brain
more slowly, particularly in the Tg2576 model where the half-life of both the endogenous murine and transgene-derived
human sAPP is nearly doubled compared to wild-type mice. The important Ab degrading enzymes neprilysin and IDE were
found to be highly stable in the brain, and soluble Ab40 and Ab42 levels in both wild-type and Tg2576 mice rapidly declined
following the depletion of APP. The cytoskeletal-associated protein tau was found to be highly stable in both wild-type and
Tg2576 mice. Our findings unexpectedly show that of these various AD-relevant protein metabolites, sAPP turnover in the
brain is the most different when comparing a wild-type mouse and a b-amyloid depositing, APP overexpressing transgenic
model. Given the neurotrophic roles attributed to sAPP, the enhanced stability of sAPP in the b-amyloid depositing Tg2576
mice may represent a neuroprotective response.
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Introduction
The brain accumulation of abnormal proteins is a common
hallmark of multiple neurodegenerative diseases. Alzheimer’s
disease (AD) brains are characterized by extracellular aggregates
of the small (40 and 42 residues) b-amyloid peptide (Ab) [1], and
intraneuronal neurofibrillary tangles, composed of hyperpho-
sphorylated tau assembled in paired helical filaments [2]. Ab is
generated by proteolysis of the ,100-kDa amyloid precursor
protein (APP), a broadly expressed type-1 transmembrane protein
that is found primarily in the trans-Golgi network, endocytic
compartments, and at the cell surface [3]. b-Cleavage of APP,
mediated by BACE1, occurs within the luminal/extracellular
domain of APP and generates two APP fragments: a large, soluble
amino-terminal fragment (sAPPb) that is secreted from the cell and
a transmembrane, carboxyl-terminal fragment (bCTF) containing
the whole Ab peptide that remains associated with the cell [4]. An
alternative pathway involves the cleavage of APP 16 residues
downstream of this site at the a-cleavage site, which is mediated by
metalloproteases [5]. Like b-cleavage, a-cleavage generates an
sAPP fragment (sAPPa) that is secreted from the cell and an aCTF
that remains membrane-associated. a-Cleavage occurs within the
Ab peptide sequence and as such prevents the generation of Ab
from a given APP molecule. Ab is generated from the bCTF by an
intramembrane cleavage (mediated by the presenilin c-secretase
complex) that occurs primarily at 40 residues, and to a lesser
extent at 42 residues, downstream from the b-cleavage site,
releasing Ab1–40 and Ab1–42 [4].
While much is known about the proteolytic processes that lead
to the generation of these APP metabolites, their subsequent
metabolism and function(s) in the central nervous system (CNS)
are not as well defined [6]. APP that is not cleaved at the a-o rb-
sites can be degraded through the lysosomal pathway [7–9]. Ab
accumulation in the brain during AD is dependent on the
misbalance of production and turnover of this peptide, with
neprilysin and insulin degrading enzyme (IDE) known to be
important Ab degrading enzymes in the brain [10,11]. The
turnover of the secreted sAPP fragments in vivo has not been
extensively examined [12], and, unlike APP, cannot be assessed
using cell culture systems where sAPP is simply secreted into the
growth media. Understanding the turnover of proteins in the
brain that play a central role in neurodegenerative diseases, such
as APP and tau, can help to explain why a protein/peptide
fragment, such as Ab, accumulates. Additionally, understanding
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intact brain is an important consideration when developing
therapeutic strategies directed at altering their levels. In the case
of APP, the fragments that are generated may have important
physiological functions related to their abundance and regula-
tion in the CNS. For example, sAPP is thought to have
neuroprotective and neurotrophic functions [13,14], which
would be unique to the CNS and dependent upon its stability
in the brain. In order to directly examine the turnover of
endogenous APP, APP metabolites, and tau in an intact brain,
we have blocked de novo protein synthesis in mice and examined
the stability of these proteins over time.
Results
Following treatment with cycloheximide, we examined by
Western blotting APP holoprotein levels in the brains of Tg2576
mice with b-amyloid deposits and wild-type littermates. Figure 1A
and 1B show that APP levels rapidly declined in Tg2576 and wild-
type mice following protein synthesis inhibition. The initial
turnover of the human Swedish APP in the Tg2576 model, which
is overexpressed at ,6-fold of the endogenous protein ([15]; see
also Figure 1A), is similar to the turnover of the endogenous APP
in a wild-type mouse, with ,40% of the pre-existing APP
degraded within the first hour. In both Tg2576 and wild-type
mice, a portion of the initial APP was found to persist up to
23 hours following the inhibition of protein synthesis, with a
greater amount of the initial APP pool persisting in the Tg2576
mice (,50%) than in the wild-type mice (,30%); p,0.001, two-
way ANOVA comparing the APP turnover in the Tg2576 and
wild-type mice.
Next, we examined the levels of sAPP in the brain following
cycloheximide treatment. Using 22C11 antibody to detect all
sAPP fragments, human and mouse and following cycloheximide
treatment, it was found that sAPP total is cleared from the brain in
the Tg2576 (top panel of Figure 1C) and wild-type mice (top panel
of Figure 1D). The half-life for sAPP total was found to be more
than 7 hours in Tg2576 mice and ,4 hours in wild-type mice
(calculated as a first-order process [16]) (Figure 1E); p,0.001, two-
way ANOVA comparing the sAPP total turnover in the Tg2576
and wild-type mice. Initial sAPP total levels in the brain of Tg2576
mice were increased relative to wild type, as is expected given
increased APP expression (see top panel Figure 1C). Moreover,
sAPP itself is more abundant in mouse brain than APP (see Figure
S1, lower panel E), consistent with the sAPP species having a
longer half-life in the brain than APP.
To further explore potential differences in the in vivo half-life of
sAPP, we differentiated in the Tg2576 mice sAPPa from sAPPb,
both human and murine (Figure 1C). In the Tg2576 mice, the
turnover of murine sAPPa (sAPPa tK .7 hours) was found to be
slower than the turnover of murine sAPPb, human sAPPa, and
human sAPPb (Figure 1F; tK ,5–6 hours) (p,0.001, two-way
ANOVA comparing murine sAPPa to the other sAPP species),
although the relative stability of all sAPP species in the Tg2576
mouse brain is in agreement with the slow turnover of sAPP total
seen in this model (Figure 1E). In wild-type mice (Figure 1D), both
the endogenous murine sAPPa and sAPPb were found to have in
vivo half-lives of ,4 hours (Figure 1G), in close agreement with the
turnover seen for sAPP total detected with 22C11 in the wild-type
mice (Figure 1E). No breakdown products were specifically
detected by the antibody against APP (C1/6.1) or the different
sAPP antibodies in these Western blot analyses.
Prior to examining the clearance of Ab in the brain, we
determined the stability of two Ab degrading enzymes:
neprilysin and insulin degrading enzyme (IDE). The levels of
these important Ab degrading enzymes do not decline rapidly
following cycloheximide treatment in either Tg2576 mice
(Figure 2A) or wild-ty p em i c e( F i g u r e2 B ) ,a n db o t hp r o t e a s e s
were readily detected following 23 hours of cycloheximide
treatment. Plaque-associated Ab is thought to be highly stable
within the brain [17]. Total Ab levels in the Tg2576 mice,
determined by formic acid extraction of plaque Ab,v a r i e d
between animals independently of cycloheximidetreatment time
(data not shown). However, the pool of soluble Ab measured by
DEA extraction normalized to formic-acid extractable Ab in a
given Tg2576 mice was found to rapidly decrease following
cycloheximide treatment (Figure 2C). The soluble Ab pool in the
Tg2576 mice decreased by ,50% at maximum, suggesting that
soluble Ab in the b-amyloid depositing mice may be in
equilibrium with plaque-associated Ab.W ea l s oe x a m i n e d
DEA extractable, soluble endogenous Ab levels in wild-type
mice (Figure 2D). Brain Ab40 and Ab42 levels decreased
rapidly, at a rate similar to that of soluble Ab in the Tg2576
mice, and consistent with the rapid depletion of precursor APP
in the brain. In comparison to the Tg2576 mice, less of the initial
Ab remained after 23 hours of cycloheximide treatment in the
wild-type mice.
Finally, we determined the in vivo turnover rate of tau. In
Tg2576 mice, the levels of tau protein (T57120) were unchanged
with cycloheximide treatment over 23 hours. Similarly, in the
wild-type mice levels of tau protein were unchanged following
protein synthesis inhibition (Figure 3A and 3B). In contrast, a
greater upward shift in the mobility of tau in the wild-type mice
compared to the Tg2576 mice following cycloheximide treat-
ment is suggestive of a robust increase in tau phosphorylation.
Consistent with this idea, the levels of phosphorylated-tau
detected by PHF-1 dramatically increased in the wild-type mice
following protein synthesis inhibition (,3.4-times at 23 hours),
whereas the change in PHF-1 signal from baseline in the Tg2576
mice following cycloheximide treatment was less (,1.5-times at
23 hours) (Figure 3A and 3C). While the initial PHF-1 signal was
less in the wild-type mice compared to the Tg2576 mice (Tg2576
,2.2-times wild-type without treatment), after 23 hours of
protein-synthesis inhibition the level of PHF-1 reactivity was
similar in both groups of mice (Figure 3C). Cycloheximide
treatment is known to cause hypothermia [18], and a decrease in
b o d yt e m p e r a t u r ei nm i c ei n c r e a s e st h el e v e l so fp h o s p h o - t a u
[19,20]. To determine whether cycloheximide-treatment in-
creases tau phosphorylation in the wild-type mice primarily as
the result of a decrease in body temperature, mice housed at
room temperature were compared to mice housed at 34uC.
When housed for 19 hours at 22uC following cycloheximide
treatment body temperature decreased by 4.8+/21.1uC( n=6 ) ,
whereas mice housed at 34uCs h o w e das m a l l e rd r o pi nb o d y
temperature (2.3+/20.4uC; n=6). Control mice showed no
change in body temperature when housed at 34uC. When
compared by Western blotting, the mice housed at 34uCh a dl e s s
of an increase in phospho-tau levels following cycloheximide
treatment (Figure 3D). Primary neurons maintained at 37uC
showed a small and transient increase in phospho-tau following
cycloheximide treatment that was also reflected in the appear-
ance of a slower migrating band in the total tau Western blot,
possibly due to differential turnover of the relevant tau kinases
and phosphatases (Figure 3E). Nevertheless, the reduction in
cycloheximide-dependent tau phosphorylation in vivo when body
temperature is maintained suggests that the bulk of the increase
in tau phosphorylation over a longer period results from a
decrease in body temperature (Figure 3D).
In Vivo APP and Tau Turnover
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e7134Figure 1. Turnover of APP and sAPP in 16-month-old Tg2576 mouse and wild-type brains following cycloheximide treatment. Western
blotting is shown oftotal proteins isolated from brain tissue followingcycloheximide treatmentofmicefor theindicated times. (A) Transgene-derived human
and endogenous APP in Tg2576 mice and endogenous murine APP in wild-type mice was detected with the anti-C-terminal APP antibody C1/6.1; b-tubulin,
which is known to be stable in the CNS [52], is shown in control Western blots. An untreated wild-type mouse (wt) is included in the Tg2576 analysis to show
the increased APP expression in this model. (B) Quantification of APP turnover in the Tg2576 and wild-type mice normalized to the band density without
cycloheximide treatment; two-way ANOVA was used to compare APP turnover in the Tg2576 and wild-type mice (p,0.001). (C) Following the indicated
cycloheximide treatment times, sAPP total was detected with 22C11 in Tg2576 mice. Human sAPPaand sAPPb were detected by Western blotting with 6E10
and 6A1, respectively, and endogenous murine sAPPa and sAPPb were detected by Western blotting with m3.2 and 242, respectively. Non-specific bands
detected by the affinity purified polyclonal 242 are shown by the APP knockout brain homogenate. (D) Levels of endogenous sAPP total, sAPPa and sAPPb
were detected by Western blotting in wild-type mice following cycloheximide treatment as described above. The graphic representations in (E)c o m p a r et h e
quantification of the levels of sAPP total in Tg2576 and wild-type mice (p,0.001). In (F), the turnover of the indicated sAPP species in the Tg2576 mice is
shown (p,0.001, comparing murine sAPPato the other sAPP species). In (G), the levels of endogenous sAPPaand sAPPbin wild-type mice is shown (p.0.5).
Throughout, quantifications are from two experiments (mean 6 SEM) as specified in the Methods section.
doi:10.1371/journal.pone.0007134.g001
In Vivo APP and Tau Turnover
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Global protein-synthesis inhibition can be used to determine the
stability of proteins in an animal, and is appealing when examining
protein turnover in the CNS as the protein-synthesis inhibitor
cycloheximide readily passes the blood-brain barrier and the
conditions for CNS-protein-synthesis inhibition in mice have been
well established [21]. Using this, we examined in the brain the
metabolic turnover of two proteins key to AD pathobiology, tau
and APP, comparing wild-type mice with a transgenic b-amyloid
depositing AD mouse model Tg2576 [15]. The turnover for a
metabolite such as the secreted sAPP species as well as
extracellular Ab cannot be extrapolated from a cell culture
system, and can only be determined in the intact brain. Moreover,
determining the impact of plaque pathology and associated gliosis
[22] on the turnover rate for tau, APP and other APP metabolites
such as sAPP also necessarily requires an intact in vivo system.
Our finding that tau is a highly stable protein in the brains of
both wild-type and Tg2576 mice is in agreement with a report of
tau protein persisting for more than 30 days during transport along
the mouse optic nerve from the retina [23], and suggests that tau
remains long-lived once delivered to the distal neurite. In both
wild-type and Tg2576 mice, the total levels of tau protein were
unchanged with as long as 23 hours of cycloheximide treatment,
and this stability of tau in vivo may predispose it to accumulation
such as occurs in AD with paired helical filament tau [24,25].
Unexpectedly, both in wild-type and Tg2576 mice the levels of
phosphorylated-tau increased following inhibition of protein
synthesis, apparently due to hypothermia. Hypothermia is a
powerful enhancer of tau phosphorylation through its effects on
the balance of kinase and phosphatase activities [19,20], although
this effect was less pronounced in the Tg2576 mice, possibly
because baseline phospho-tau is higher in these mice [26–28].
The rapid turnover of endogenous APP following protein
synthesis inhibition in the brain is consistent with what has been
reported by pulse-chase of cultured rodent neurons and glia [29].
APP is transported by rapid anterograde transport in neurons,
with most of its processing apparently occurring at the distal
neurite [30]. Following metabolic labelling of retinal ganglion cells,
Lyckman et al. [31] found that APP, once transported to the
presynaptic termini, had a half-life of less than 4 hours. Consistent
with these reports, our findings present a global picture of APP
metabolism in the brain showing a rapid bulk-turnover of the
holoprotein, both under normal expression levels in wild-type mice
and with APP overexpression and plaque pathology in aged
Tg2576 mice. Indeed, in spite of the greater APP expression in the
transgenic mice the initial turnover of APP is similar in Tg2576
and wild-type mice, although a greater proportion of APP stably
persists following extended cycloheximide treatment in the APP
overexpressing transgenics.
The bulk flow of the CSF in a mouse brain, measured by inulin
[32] or albumin [33] transport, is approximately 2–3 hours, which
is similar to the turnover of sAPP in a wild-type mouse brain and
suggests that this soluble APP metabolite may diffuse in the brain
Figure 2. Turnover of neprilysin, IDE and Ab levels in 16-month-old Tg2576 and wild-type mouse brains following cycloheximide
treatment. NeprilysinandIDEturnover is shown byWestern blotting in Tg2576 (A) andwild-type mice (B); b-tubulinis shownas a control.(C) Theratio
of DEA-extractable to formic acid-extractable humanAb40 andAb42 in Tg2576mice were measured by sandwich ELISA at the indicatedtimes following
cycloheximide treatment (mean 6 SEM). (D) Turnover of endogenous DEA-extractable Ab40 and Ab42 levels in wild-type mice (mean 6 SEM).
doi:10.1371/journal.pone.0007134.g002
In Vivo APP and Tau Turnover
PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e7134Figure 3. Metabolism of tau following protein synthesis inhibition. (A) Western blots are shown using an antibody that recognizes tau
independent of its phosphorylation status (T57120, top panels) and an antibody that detects a phospho-epitope on tau (PHF-1, bottom panels) in
Tg2576 mouse brain and in wild-type mouse brain. Total brain proteins were analyzed as in Figure 1. (B) Change in the intensity of the T57120 signal
following cycloheximide treatment in Tg2576 and wild-type mice is shown (mean 6 SEM). (C) Change in the intensity of the PHF1 signal following
cycloheximide treatment in Tg2576 and wild-type mice is shown (mean6SEM). Signal intensity is normalized to the PHF1 signal in wild-type mice
without treatment (inserted Western blot). (D) Tau levels detected with T57120 and PHF-1 antibodies in wild-type mouse brain following
cycloheximide treatment when mice were housed at ambient temperature (22uC) or at 34uC for 19 hours. b-tubulin is shown as a loading control. (E)
Tau levels in primary neurons were detected by Western blotting with T57120 and PHF-1 antibodies after cycloheximide treatment as indicated. b-
tubulin is shown as a loading control.
doi:10.1371/journal.pone.0007134.g003
In Vivo APP and Tau Turnover
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catabolism [16]. However, the turnover of sAPP in the brain was
found to be slower in the Tg2576 mouse than in a wild-type
animal. sAPP has been shown to support cell survival, neurite
outgrowth, synaptogenesis, synaptic plasticity, can modify the
response of neurons to injury, and can substantially rescue CNS
deficits in an APP null mouse [34–39]. The increased stability of
sAPP in Tg2576 mice relative to wild-type mice is consistent with a
greater need for neurotrophic support in the b-amyloid containing
brain [40] and may reflect an ongoing role for sAPP in supporting
neuron function in the context of b-amyloid toxicity, neuron stress,
and inflammatory responses [34–38]. In the context of the greater
overall stability of sAPP in the Tg2576 mice, substantial
differences were also seen in the turnover of the specific sAPP
species, with the murine sAPPa the most stable of the sAPP
species. Given that the Swedish mutation in the transgene human
APP drives b-cleavage and sAPPb production [41,42], the
disproportionate levels of sAPPb in the Tg2576 mice may impact
the turnover of the relatively underrepresented sAPPa. Addition-
ally, Ab pathology may alter the turnover of sAPPa through an
interaction in the brain parenchymal between the sequence
homology at the C-terminus of sAPPa with the N-terminus of Ab.
Additionally, overexpression of sAPP in the Tg2576 mouse may
overload the degradation pathway, although the differences in the
metabolism between human and murine sAPP species, with
murine sAPPa showing the longest half-life, suggests that species
differences and/or differences in the handling of the Swedish-
mutation-containing sAPP fragments also play a role in brain
sAPP turnover in the b-amyloid depositing mouse model.
We find that endogenous Ab, both Ab40 and Ab42, is rapidly
degraded following cycloheximide treatment and the depletion of
pre-existing APP. Following c-secretase inhibition, Ab micro-
dialysis measurements have given a half-life for extracellular Ab of
,2 hours [13], and Savage et al. [14] have shown that shifting
APP processing to the a-secretase pathway resulted in a decline in
total brain Ab with a half-life between 1 and 2.5 hours. Our
findings, which used a different experimental approach that does
not specifically alter an APP cleavage step, further support the
conclusion that Ab is rapidly cleared from the normal brain.
Soluble Ab in the b-amyloid plaque containing Tg2576 mice
showed a similar and rapid decrease following cessation of protein
synthesis, again with Ab40 and Ab42 turnover being similar.
These findings indicate that the soluble Ab pool in a brain
containing b-amyloid plaque is similarly accessible to degradation
as is soluble Ab in a normal brain. The reduction plateau reached
in the Tg2576 mice for soluble Ab, which is likely to be in
equilibrium with plaque-associated Ab, may represent additional
DEA-extractable Ab being liberated from b-amyloid plaques over
time in the brain. While brain APP is metabolized rapidly in both
wild-type and an APP transgenic mice, our findings unexpectedly
show that sAPP is more stable in vivo in the b-amyloid containing
Tg2576 brain when compared to wild-type mice. Additionally, the
rapid turnover of a soluble pool of Ab is similar in the wild-type
and the Tg2576 mice in spite of the significant accumulation of
plaque-associated Ab in the brains of the transgenic mice. The
slower turnover of sAPP in the mice with plaque pathology
suggests that this neurotrophic APP metabolite may have an
important role in the b-amyloid containing brain.
Materials and Methods
Cycloheximide treatment
All experiments involving mice received prior approval from the
Nathan Kline Institute Animal Care and Use Committee. Sixteen-
month-old Tg2576 mice (overexpressing Swedish-mutant human
APP) [15] and wild-type littermates on a Swiss Webster x DBA/
C57BL6 F1 background were injected ip with 4.8 mg cyclohex-
imide in 150 ml isotonic saline (containing 20 mM HEPES, pH 8),
which has been shown to block protein synthesis in the brain of
mice [21]. Mice were returned to their home cage, maintained at
room temperature (22uC), sacrificed at the times indicated, and
brain tissue was dissected and flash-frozen prior to storage at
280uC. The quantification of Western blot band density in
Figure 1B, 1E, 1F, 1G and 3A is from two experiments with a total
for both wild-type and Tg2576 of three mice at 0 and 23 hours
cycloheximide treatment, two mice at 2, 4 and 6 hours treatment
and one mouse at 1, 3, 5 and 7 hours treatment. In the tau
experiments shown in Figure 3B, half of the mice were held in
their home cage at a temperature of 34uC following cycloheximide
injection.
Cell cultures
Primary rat neuronal cultures were established from E18
embryos as previously described [43], and maintained in
Neurobasal Media (minus L-glutamine and phenol red) containing
B27 supplement, penicillin-streptomycin and Gluta MAX-1 (all
from Invitrogen, Carlsbad, CA) for 10 days. Primary neurons were
treated with 40 mg of cycloheximide per 1 ml media for the times
indicated prior to lysis and recovery of proteins for Western
blotting as previously described [44].
Antibodies
Antibodies C1/6.1 and m3.2 were generated in our laboratory:
C1/6.1 recognizes the carboxyl-terminal cytoplasmic domain of
APP [44], while the epitope for m3.2 has been determined to be
within residues 10–15 of murine Ab by mapping against synthetic
peptides m3.2 recognizes murine APP, sAPPa and Ab (See Figure
S1). 22C11 was purchased from Millipore (Temecula, CA) and
recognizes an N-terminal APP epitope common to the human
and murine proteins. Monoclonal antibody 6E10 (Covance,
Princeton, NJ), which recognizes residues 1–16 of human Ab,w a s
used to detect human sAPPa.R a b b i tp o l y c l o n a la n t i - s A P P b
antibody 242 recognizes only wild-type (murine or human) sAPPb
but not Swedish-mutant-derived sAPPb [45], and mouse
monoclonal antibody 6A1 recognizes sAPPb containing the
Swedish mutation but not the wild-type sequence [46]. These
sAPP antibodies (242, 6A1) recognize cleaved sAPP fragments
and are not cross-reactive with uncleaved APP. Total tau protein
was detected by a phosphate-independent anti-tau monoclonal
antibody (Tau T57120; BD Bioscience, San Jose, CA). PHF-1
recognizes tau protein phosphorylated at serine residues 396 and
404 [47]. Neprilysin was detected with the monoclonal antibody
56C6 (CD10) (Novacastra, Newcastle, UK), and IDE with the
rabbit polyclonal antibody IDE1 ([11]; a gift of Dr. Dennis
Selkoe).
Brain Processing, Western blotting, Detection of APP
Metabolites
Ten-percent (weight-to-volume) homogenates were prepared
(in 250 mM sucrose, 20 mM Tris base, 1 mM EDTA, 1 mM
EGTA and protease inhibitors) from hemibrains lacking the
olfactory bulb and cerebellum [48], and these homogenates
were subsequently used for Western blotting and extraction
prior to Ab sandwich ELISA. For Western blot analysis,
membranes were incubated in the appropriate primary
antibody (2 mg/ml) overnight and HRP-coupled secondary
antibody for 1 hour.
In Vivo APP and Tau Turnover
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Murine Ab levels were determined by sandwich ELISA using
aliquots of the 10% sucrose homogenate. Soluble Ab from an
aliquot of the sucrose homogenates of wild-type and Tg2576 mice
was extracted by diethylamine (DEA) [48]; separately, formic-acid
extraction of another aliquot of the sucrose homogenate was used
to detect b-amyloid plaque-associated Ab in the Tg2576 mice. In
combination with Ab40 and Ab42 C-terminal specific monoclonal
antibodies (capture antibodies JRF/cAb40/10 and JRF/cAb42/
26) [49], horseradish peroxidase-conjugated m3.2 was used to
detect endogenous murine Ab in Ab40- and Ab42-specific
sandwich ELISAs [50]. Similar ELISAs using JRF/AbN25 [51]
were used to detect human Ab in the Tg2576 mouse brains.
ELISA results are reported as the mean 6 SEM in fmol Ab per g
wet brain, based on standard curves using synthetic murine and
human Ab1240 and Ab1242 peptide standards (American
Peptide).
Statistics
Western blots were quantitated using ImageJ (http://rsb.info.
nih.gov) and data analysis and graphs were plotted on GraphPad
Prism v.5 (GraphPad Software, San Diego, CA, USA). Curve
fitting and statistical two-way analysis of variance (ANOVA) were
performed.
Supporting Information
Figure S1 Characterization of the monoclonal antibody m3.2.
Antibody m3.2, which was generated in our laboratory against a
synthetic peptide corresponding to residues 1–15 of murine Ab,
binds specifically to murine APP, sAPPa and Ab. A. Specificity of
m3.2 antibody for murine Ab compared to human Ab shown by
immunoprecipitation and Western blotting. Equal amounts (3 mg)
of synthetic murine Ab42 and human Ab42 were immunoprecip-
itated overnight [44] with m3.2 and 6E10 antibodies as indicated.
The immunoprecipitate was resolved by SDS-PAGE, transferred
to membrane, and probed with m3.2 antibody. Murine Ab was
detected in the m3.2 immunoprecipitation of synthetic murine
Ab42; human Ab was not detected. IgG heavy and light chain
reactivity is with the secondary detection antibody. B. Human Ab
was immunoprecipitated by antibody 6E10 and not detected by
antibody m3.2. As was done in S1A, synthetic human and murine
Ab were immunoprecipitated as indicated. Human Ab was
immunoprecipitated and detected by antibody 6E10, while
antibody m3.2 showed no reactivity for the human Ab.C .
Specificity of antibody m3.2 for murine APP metabolites. Western
blotting using antibody m3.2 of human control and AD brain and
wild-type and aged Tg2576 mouse brain is shown. Consistent with
peptide mapping showing that the m3.2 antibody epitope is within
residues 10–15 of murine Ab (data not shown), antibody m3.2
detected murine APP and co-migrating sAPPa in the mouse brain
extract, but did not detect any proteins in the human brain
extracts. Additionally, antibody m3.2 detected the abundant
murine Ab co-deposited in aged Tg2576 mouse brain. D.
Antibody m3.2 reactivity with mouse brain extract is blocked by
co-incubation with synthetic murine Ab. Wild-type and aged
Tg2576 mouse brain extracts were resolved by SDS-PAGE as
indicated. Synthetic murine Ab42 or synthetic human Ab was
added to the antibody m3.2 binding solution as indicated (1 mg/ml
murine or human Ab,2mg/ml m3.2 antibody) 1 hour prior to
membrane incubation. APP metabolites were not detected with
the addition of competing synthetic murine Ab42. The addition of
synthetic human Ab42 did not interfer with m3.2 reactivity with
murine APP metabolites in the mouse brain. E. Antibody m3.2
detects both APP and sAPPa in mouse brain. Mouse brain
homogenates were subjected to centrifugation at 100,0006g for
1 hour as previously described [48]. Equivalent amounts of the
membrane pellet containing APP and the supernatant containing
soluble sAPP were resolved by SDS-PAGE and probed with either
antibody m3.2 or 22C11 as indicated. The subtle mobility shift in
the smaller sAPP species is shown for sAPPa (m3.2) and total sAPP
(22C11) compared to the membrane-associated APP in the pellet
fractions. These Western blots also demonstrate the steady-state
abundance of sAPPa (m3.2) and total sAPP (22C11) relative to
APP, consistent with the slower turnover of sAPP in the mouse
brain.
Found at: doi:10.1371/journal.pone.0007134.s001 (9.70 MB TIF)
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